Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

62Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

Abstract

The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative cardiovascular and cerebrovascular safety of adding a second long-acting bronchodilator in patients with COPD. We identified a cohort of COPD patients, new users of LABA or the LAMA tiotropium during 2002–2012, from the UK Clinical Practice Research Datalink. Using high-dimensional propensity scores, each patient adding a second bronchodilator was matched with a patient who remained on monotherapy. Patients were followed for 1 year for the occurrence of acute myocardial infarction (AMI), stroke, heart failure and arrhythmia. The cohorts included up to 31174 patients adding a bronchodilator matched to 31174 patients remaining on bronchodilator monotherapy. Adding a long-acting bronchodilator, compared to remaining on monotherapy, was not associated with an increased risk of AMI (hazard ratio (HR) 1.12, 95% CI 0.92–1.36), stroke (HR 0.87, 95% CI 0.69–1.10) or arrhythmia (HR 1.05, 95% CI 0.81–1.36), but the risk was elevated for heart failure (HR 1.16, 95% CI 1.03–1.30). Adding a second long-acting bronchodilator in the real-world-setting treatment of COPD does not increase the risk of most cardiovascular events. The modest increase for heart failure warrants further investigation.

Cite

CITATION STYLE

APA

Suissa, S., Dell’Aniello, S., & Ernst, P. (2017). Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. European Respiratory Journal, 49(5). https://doi.org/10.1183/13993003.02245-2016

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free